Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-HLRCC-TC1 neutralizing antibody
- Development stage
- Preclinical
- Lead developer
- University of Michigan
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
The anti-HLRCC-TC1 neutralizing antibody is a discovery-stage biologic agent designed to target HLRCC-TC1, a protein identified as a novel therapeutic candidate in hereditary leiomyomatosis and renal cell carcinoma (HLRCC). HLRCC is an aggressive kidney cancer associated with germline mutations in the fumarate hydratase (FH) gene. Research conducted at the University of Michigan demonstrated that HLRCC-TC1 is specifically overexpressed in HLRCC tumors and other high-risk renal cell carcinomas. In preclinical models, the use of neutralizing antibodies to HLRCC-TC1 significantly inhibited the proliferation of the HLRCC-derived cell line UOK262, validating the protein as a potential target for therapeutic intervention.
- Other names
- neutralizing antibody targeting HLRCC-TC1anti-HLRCC-TC1 antibodyanti-HLRCC-TC-1 antibodyanti-HLRCC-TC 1 antibody
02
Targets
ASIC1a
Beyond the preview
Go deeper on anti-HLRCC-TC1 neutralizing antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-HLRCC-TC1 neutralizing antibody.